RPS6KA1 and prostate carcinoma: The RSK1 and/or RSK2 isoforms are overexpressed in many tumors, including breast and prostate carcinomas and osteosarcoma [23,24,25]; these isoforms promote tumor growth, survival, invasion and metastasis [25,26], and for this reason, they constitute promising anti-tumor targets.